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oseph L. Witztum, MD†
an Diego, California; and Vienna, Austria
t is now widely recognized that the evolving atherosclerotic
esion has nearly all of the characteristics of a chronic
nflammatory disease, including the active participation of
any arcs of immune function. That immune mechanisms
lay an important, if not dominant, role once atherosclerosis
as been initiated is attested to by scores of examples in
hich manipulations of both adaptive and innate immune
unction have profoundly impacted atherogenesis in murine
odels, accelerating it or providing atheroprotective influ-
nces (1–5).
ole of Immune Function in Atherogenesis
ost cellular components of the immune response such as
onocyte/macrophages, dendritic cells, T cells, NKT and
K cells, and mast cells are present in lesions. Neutrophils
re curiously absent, whereas B cells are not usually found in
he lesion itself but in the immediate adventitia and in
raining lymph nodes. In addition, noncellular components
f immunity are prominently found in established lesions,
ncluding immunoglobulins, in part bound to specific
isease-related antigens, such as oxidized low-density
ipoproteins (oxLDL) (6).
See page 540
In general, T lymphocytes appear to mediate a net
roatherogenic effect, although there is a growing body of
vidence that special subsets of regulatory T cells may provide
theroprotective properties as well. B cells, however, appear to
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nhibit atherosclerosis, but there is no financial backing.onvey an atheroprotective function. For example, B-cell–
eficient low-density lipoprotein receptor (LDLR)/ mice
eveloped increased atherosclerosis (7), and splenectomy of
polipoprotein (apo) E/ mice, which decreased anti-
xLDL antibodies, also resulted in increased atherosclero-
is, and this effect could be reversed by infusion of B cells
rom aged apoE/ mice (8). However, it is unclear which
opulation of B cells conferred this protection and whether
his was due solely to humoral immunity or, conceivably, to
newly emerging regulatory role of B cells (9). Further-
ore, in contrast to most studies indicating an antiathero-
enic role for T cells, passive transfer of T cells into the
plenectomized mice also conferred atheroprotective prop-
rties (8). These data suggest the important principle that
he impact of a given immune component may well be
ontext dependent and caution must be used in study and
nterpretation of the complex roles of immune function in
therogenesis.
xidation of LDL Generates
mmunodominant Epitopes in Lesions
here are many potentially important antigens within
therosclerotic lesions, including bacterial and viral anti-
ens, heat shock proteins, and variously modified proteins.
here is now a large body of evidence that “oxidation-
pecific” neo-epitopes derived from the oxLDL constitute
ne class of immunodominant antigens. Indeed, both adap-
ive and innate arcs of immunity are involved in an orches-
rated response to the many oxidized lipids and oxidized
ipid-apolipoprotein B adducts generated (2). Two widely
sed models have been studied: LDL oxidized by exposure
o copper (Cu-oxLDL) and malondialdehyde (MDA) mod-
fication of LDL (MDA-LDL). Our laboratory reported
he presence of autoantibodies to epitopes of Cu-oxLDL
nd MDA-LDL in rabbits and humans and demonstrated
he presence of such autoantibodies in atherosclerotic le-
ions, in part as components of immune complexes with
xLDL. Change in titers of autoantibodies to Cu-oxLDL
nd MDA-LDL in murine models of atherosclerosis par-
lleled the progression or regression of lesion formation. We
ubsequently proposed that an immunization strategy could
e developed to ameliorate the progression of atherosclero-
is by showing that immunization of Watanabe heritable
yperlipidemic rabbits and LDLR/ mice with homolo-
ous MDA-LDL could inhibit atherogenesis (10,11).
hese observations have been confirmed and extended by
thers (12,13). Similarly, immunization with Cu-oxLDL is
lso atheroprotective (14,15). The mechanisms by which
uch immunizations produce atheroprotective immunity are
oorly understood, and, in part, studies of these mecha-
isms are hindered by the fact that each of the immunogens
sed, Cu-oxLDL and even MDA-LDL, contains a com-
lex and varied set of epitopes, which independently may
ffect different arcs of adaptive and innate immunity. Fur-
hermore, although immunization of animals with modified
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Editorial Comment August 7, 2007:547–50omologous LDL is atheroprotective, a similar vaccine
pproach to test in humans would require the derivatization
f autologous LDL, which would not be practical for large
opulations. To develop a generalized and safe vaccine
equires the identification of the specific immunogenic
xidation-specific epitopes that provide the atheroprotective
mmunity. Ideally, such defined chemical moieties could
hen be formulated into one or more immunogenic vaccine
pproaches that could be widely administered.
xidation-Specific Epitopes Are
ecognized by Natural Antibodies
ur original selection of MDA-LDL as an immunogen was
ased on the fact that it already represented a more
estricted set of epitopes than Cu-oxLDL. However, reac-
ions of MDA with -amine of lysine are complex and yield
variety of adducts, which will need to be defined in future
tudies.
In the case of Cu-oxLDL, an even greater array of
hemically modified lipids and lipid-protein adducts are
enerated. Cholesterol-fed apoE-deficient mice have very
igh autoantibody titers to oxLDL, particular immunoglob-
lin M (IgM), which enabled the cloning of a large panel of
gM B-cell hybridomas from the spleens of these mice with
pecificity for Cu-oxLDL (16). Each of these, such as the
rototypic EO6, bound to both the lipid and the apoB
oiety of oxLDL, and specifically to the phosphocholine
PC) headgroup of oxidized phospholipids (oxPL), such as
-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phospho-
holine (POVPC), but not the PC of native phospholipids
17). Importantly, EO6 inhibited the uptake of oxLDL by
acrophage scavenger receptors CD36 and SR-BI (18,19),
s did POVPC linked to a peptide. Furthermore, similar to
he binding to EO6, the PC moiety of oxPL was sufficient
tself to mediate binding of oxLDL to CD36 (20). These
ata suggested that PC-specific IgM, such as EO6, could
nhibit oxLDL uptake in vivo and in that way decrease
acrophage uptake and foam cell formation.
Because all of these cloned autoantibodies were IgM,
hich are thought in large part to represent natural anti-
odies in uninfected mice, the genetic origins of the
omplementary determining region determining the
ntigen-binding site of these IgM were revealed to be
enetically identical to a well characterized B-1 cell clone,
15, described over 30 years ago (21). T15 natural anti-
odies bind to PC covalently linked to the cell-wall poly-
accharide (C-PS) of pathogens and provide optimal pro-
ection to mice from lethal infection with Streptococcus
neumoniae (22). EO6/T15 also bound to the PC of oxPL
resent on the plasma membrane of apoptotic cells, which
re known to be undergoing oxidative stress, but did not
ind to viable cells. These studies demonstrated molecular
imicry between the PC of oxPL present on oxLDL and
poptotic cells, on one hand, and the PC moiety present on
neumococcus and many other infections pathogens, on the pther hand. This dual specificity for microbial and “self”-
ntigens has been described as a characteristic of natural
ntibodies (23).
The fact that the same T15 natural antibody that blocked
he uptake of oxLDL by macrophages also bound the PC of
ommon microbial pathogens suggested that the natural
gM antibodies may ameliorate atherosclerosis. To test this
ypothesis, cholesterol-fed LDLR/ mice were immu-
ized with heat-inactivated PC-containing pneumococci,
hich induced a near monoclonal expansion of anti-oxLDL
gM (predominantly of the T15 clonotype) and significantly
educed atherosclerosis as measured at the aortic valve (24).
otably, there was essentially no induction of IgG titers to
xLDL. Plasma of these immunized mice had an enhanced
bility to inhibit the uptake of oxLDL by macrophages.
hese data support the idea that anti-PC IgM antibodies of
he T15 idiotype are atheroprotective in mice. Indeed,
nfusion of such an anti-PC IgM into apoE/ mice
nhibited accelerated vein graft atherosclerosis, although
his failed to inhibit progression of lesions in native athero-
clerosis (25).
mmunization With PC-KLH
roduces Atheroprotection
n the current issue of the Journal, Caligiuri et al. (26) use
nother technique to enhance the titers of PC-specific
ntibodies in plasma of apoE-deficient mice. Mice immu-
ized with PC covalently linked to the immunogenic
eterologous protein keyhole limpet hemocyanin (KLH)
ad a 40% decrease in the extent of lesions measured at the
ortic root compared with mice immunized with KLH
lone or with phosphate-buffered saline (PBS). Importantly,
hese immunizations were conducted in the presence of
pG adjuvant, previously shown not to influence athero-
enesis. Although the mechanisms by which the PC-KLH
mmunizations induced atheroprotection are unknown, ex-
eriments suggested that sera from PC-KLH–immunized
ice decreased uptake of oxLDL compared with sera of
BS-immunized mice. This might contribute to decreased
oam cell formation, consistent with earlier experiments
ith sera of pneumococcal immunization. However, in that
arlier experiment (24), there was only an increase in IgM
iter to oxLDL in plasma, reflecting the predominant TI-2
esponses, mediated primarily through induction of natural
-1 cells. Because IgM do not bind to receptors on
acrophages, they have the ability to bind to and block
xLDL uptake by macrophage scavenger receptors. In
ddition, IgM are increasingly recognized to have important
mmunomodulatory properties. In contrast, mice immu-
ized with PC-KLH had increases in both IgG and IgM,
onsistent with major histocompatibility complex (MHC)
lass II T-cell–mediated responses. Theoretically, the pres-
nce of oxLDL/IgG immune complexes could lead to
ross-linking of macrophage Fc receptors, activation of
roinflammatory responses, or even enhanced uptake of
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August 7, 2007:547–50 Editorial CommentxLDL via Fc receptors favoring foam cell formation.
ndeed, global Fc receptor deficiency confers atheropro-
ection in apoE/ mice, indicating a proatherogenic role
or the engagement of such receptors (27). Because different
gG isotypes are known to bind different Fc receptors with
ifferent affinities and to have functionally different activi-
ies, a detailed analysis of the IgG isotypes induced by this
mmunization strategy may provide further insight.
Nevertheless, the net impact of increasing the anti-PC
iters was atheroprotection in the setting tested. However,
he long-range impact of this strategy needs to be tested, as
ell as the impact on atherogenesis at other sites in the
ortic tree, because recent experience clearly suggests that
nterventions can not only be site-specific but can impact
esion formation differentially at different stages of lesion
evelopment (28). Furthermore, the consequences of the
nusual localization of B cells within the lesions reported in
he immunized mice of the present study needs to be
nderstood.
pplication of Anti-PC
mmunization Strategy in Humans
he study by Caligiuri et al. (26) confirms and extends the
bservation that an immunization strategy that enhances
nti-PC antibodies in mice is atheroprotective. Because the
C of KLH and that of the cell wall of S. pneumoniae shows
mmunologic identity to the PC of oxLDL, it would seem
hat such an immunization strategy would be applicable to
umans. Indeed, it was demonstrated that the sera of
atients recovering from pneumococcal pneumonia con-
ained IgM antibodies to pneumococcal C-PS that signifi-
antly correlated with levels of anti-oxLDL IgM antibodies
n the same serum sample (24). Normal serum IgM in
umans has been shown to bind PC (29,30) and sera of
atients, with high titers of anti-PC IgM also bound to
poptotic cells (31). These data suggest that humans also
ave PC-specific IgM antibodies with microbial/oxLDL/
poptotic cell cross-reactivity. Notably, several recent stud-
es suggest an inverse relationship between IgM titers to
xidation-specific epitopes and cardiovascular disease (32–
4). Thus, these data support the idea that atheroprotective
ntibodies (and/or associated immune responses) do occur.
owever, there are also differences in the anti-PC responses
n humans. Unlike in mice, IgG antibodies—in particular,
gG2—dominate the anti-PC response in humans (35),
nd patients with periodontal disease have increased
nti-PC IgG2 titers exhibiting cross-reactivity between
ental plaque bacteria and oxLDL (36).
Because children and high-risk adults are currently being
mmunized against pneumococcus, one might ask if this
ould be logically expected to provide atheroprotective
mmunity. In mice, the TI-2 immune response to PC occurs
rimarily through induction of natural B-1 cells and is
obust. In contrast, in young children and in older adults
esponses to TI-2 antigens are blunted and responses to PCre insufficient to provide immunity. For this reason, current
neumococcal PS vaccines are made from multiple serotypes
usually 17 or, more recently, 23), which are covalently
oupled to a variety of immunogenic carrier proteins,
ncluding diphtheria toxoid, tetanus toxoid, and meningo-
occal outer membrane complex. In turn, this leads to classic
HC-II responses to antigens other than PC. Further,
uch TI-2 antigens are thought to impair adaptive re-
ponses, and attempts have been made to reduce the
resence of PC in such vaccines. Indeed, a recent brief
eport failed to find increases in oxLDL titers in a small
ohort of children and adults immunized with the 23-valent
accine (37). Nevertheless, in principle, if it were possible to
evelop optimal immunization strategies that led to im-
une responses directed against PC, as occurred in mice
mmunized with S. pneumoniae or PC-KLH, this might be
f value in limiting the progression of lesion formation in
umans. Such a strategy might be applicable to adults of
oung or middle age, when initiation and progression of
therosclerosis occurs.
The study by Caligiuri et al. (26) adds to a growing body
f work demonstrating the feasibility of development of a
accine approach to inhibiting the progression of athero-
clerosis. Identification of atheroprotective antigens and
evelopment of novel vaccine approaches will be required
or the implementation of such a strategy. Obviously a great
eal of work will be needed to demonstrate that this
pproach can be effective and safe in humans. However, the
ossibility of retarding the development of this ubiquitous
isease by a vaccine approach that is widely applicable is well
orth the painstaking research that will be required to bring
his idea to fruition.
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